
Opinion|Videos|August 26, 2024
Use of PRO in Atopic Dermatitis Clinical Practice
Jonathan Silverberg, MD, PhD, MPH, offers insights on the role of patient-reported outcomes in informing treatment decisions for patients with atopic dermatitis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Patient-reported outcomes (PRO) are important in atopic dermatitis and are increasingly being incorporated in clinical trials.
- Which PRO are you using in your practice?
- Which PRO are you using in your practice?
Advertisement
Related to this article

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Advertisement
Advertisement
Trending on HCPLive
1
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
2
FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCM
3
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
4
Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD
5

